Gemini Therapeutics, Inc. (GMTX): Price and Financial Metrics


Gemini Therapeutics, Inc. (GMTX): $13.50

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GMTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GMTX Stock Price Chart Interactive Chart >

Price chart for GMTX

GMTX Price/Volume Stats

Current price $13.50 52-week high $14.10
Prev. close $1.35 52-week low $1.16
Day low $13.50 Volume 6,380
Day high $14.10 Avg. volume 189,291
50-day MA $1.68 Dividend yield N/A
200-day MA $1.57 Market Cap 584.93M

Gemini Therapeutics, Inc. (GMTX) Company Bio


Gemini Therapeutics, Inc. operates as a precision medicine company. The Company focuses on dry macular degeneration which is a disease comprised of numerous genetic variants. Gemini Therapeutics serves customers worldwide.


GMTX Latest News Stream


Event/Time News Detail
Loading, please wait...

GMTX Latest Social Stream


Loading social stream, please wait...

View Full GMTX Social Stream

Latest GMTX News From Around the Web

Below are the latest news stories about GEMINI THERAPEUTICS INC that investors may wish to consider to help them evaluate GMTX as an investment opportunity.

7 Short-Squeeze Stocks for Bold Contrarians to Consider

While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists.

Josh Enomoto on InvestorPlace | November 21, 2022

Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)

Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today the initiation of AURORA, a Phase 2 clinical study of bitopertin in adults with EPP. Bitopertin is an oral, selective inhibitor of glycine transporter 1 (GlyT1) designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX (

Yahoo | October 31, 2022

Gemini Therapeutics and Disc Medicine Announce Merger Agreement

WAYLAND, Mass. & WATERTOWN, Mass., August 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) ("Gemini") and Disc Medicine, Inc. ("Disc"), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Disc’s pipe

Yahoo | August 10, 2022

Insider Buying: Braden Leonard Just Spent US$75k On Gemini Therapeutics, Inc. (NASDAQ:GMTX) Shares

Even if it's not a huge purchase, we think it was good to see that Braden Leonard, a Gemini Therapeutics, Inc...

Yahoo | April 15, 2022

Gemini Therapeutics Reports 2021 Financial Results

Remote-First-Company/Mass., March 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.

Yahoo | March 10, 2022

Read More 'GMTX' Stories Here

GMTX Price Returns

1-mo N/A
3-mo -21.97%
6-mo -14.56%
1-year -31.12%
3-year N/A
5-year N/A
YTD N/A
2022 0.00%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6601 seconds.